Previous 10 | Next 10 |
2024-05-01 06:37:13 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quar...
2024-04-30 11:53:23 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 Please replace the photo for release dated April 24, 2024 wi...
2024-04-24 10:23:46 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 United Therapeutics Corporation (Nasdaq: UTHR ), a publi...
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...
Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fib...
2024-03-31 08:00:00 ET More on Liquidia Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Liquidia gains after court win in pat...
2024-03-28 16:24:45 ET Read the full article on Seeking Alpha For further details see: Liquidia gains after court win in patent dispute with United Therapeutics
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...